Medical Records Access Fairness Act of 2026

1) HR 7790, the Medical Records Access Fairness Act of 2026, was introduced on March 4, 2026, and referred to the House Committee on Energy and Commerce. It has one cosponsor (Rep. Beatty, D-OH) and is in the earliest legislative stage. The bill is not law and faces a lengthy path: committee hearings, markup, floor vote, Senate passage, and presidential signature—none of which are guaranteed in the current divided 119th Congress. 2) The bill does NOT authorize or appropriate any funding. It imposes a compliance mandate on healthcare providers—requiring free electronic access to health records except for limited exceptions. Providers must absorb the cost of upgrading IT systems to comply. No federal dollars flow to any company; instead, the leverage is that providers will need to hire health IT vendors to manage compliance, creating derived demand. 3) Structural winners would be health IT services providers. DXC Technology ($DXC) is positioned as a healthcare IT services provider, but its primary business is legacy IT services and consulting across multiple sectors—healthcare is not its dominant revenue driver. Pure-play health IT companies like Epic Systems (private), Cerner (now Oracle Health, $ORCL), or athenahealth would be more directly affected but are either private or not pure-play enough for a clear causal chain at this stage. The bill text does not name any specific companies or technology platforms. 4) Real market data shows DXC at $11.53 as of April 30, 2026, within 2.7% of its 52-week low of $11.23. The stock has declined 2.95% over the past week and 8.27% over the past month, with a consistent downtrend from $12.97 on April 17. There is no evidence that the introduction of this bill on March 4 had any measurable impact on DXC's price—the decline is likely driven by broader sector weakness or company-specific factors. 5) Timeline: The bill is at the very first stage (referred to committee). No hearings have been scheduled. No companion bill exists in the Senate. With only 2 sponsors (both Democrats) and no Republican cosponsors, bipartisan support is absent. The 119th Congress runs through January 2027, and this bill faces extremely low odds of enactment in its current form.